License was Connect Biopharma Holdings’s largest product and service line in fiscal 2024, bringing in $24.40M of $26.00M (94%).
| Product and Service | FY 2024 |
|---|---|
| License | $24.40M |
| Clinical Trial Reports | $1.60M |
| Total | $26.00M |
Connect Biopharma Holdings brought in $26.00M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. License was the largest at $24.40M (93.8%), ahead of Clinical Trial Reports at $1.60M (6.2%).
Connect Biopharma Holdings (CNTB) reports its revenue by product and service. In fiscal 2024, License was its largest product and service line, bringing in $24.40M (93.8% of the total), followed by Clinical Trial Reports at $1.60M (6.2%).
License was Connect Biopharma Holdings' largest product and service line in fiscal 2024, bringing in $24.40M, or 93.8% of the $26.00M total across its two product and service lines.
Every figure comes from Connect Biopharma Holdings' annual financial filings, as reported. Each line keeps the name Connect Biopharma Holdings gives it, and years follow its fiscal calendar.
Connect Biopharma Holdings' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.